CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to these treatments alone and in combination.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany rak piersi (stadium III lub IV) bez receptora HER2 (trojujemny lub wrażliwy na hormony)
- •Wiek 18 lat lub więcej
- •Ogólny stan zdrowia pozwalający na leczenie (skala ECOG 0-2)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Postęp choroby potwierdzona badaniami obrazowymi lub wynikami patologicznymi mimo poprzedniego leczenia
- •Wystarczające wyniki badań krwi: białe krwinki ≥1500, płytki ≥100, hemoglobina ≥8, funkcja nerek i wątroby w normie
- •Dla raka trojujemnego: pierwsze do czwarte leczenie, wcześniej maksymalnie 3 schematy chemioterapii
- •Zgoda na stosowanie antykoncepcji podczas i przez 6 miesięcy po badaniu klinicznym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- June 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
University of Chicago Comprehensive Cancer Center
Chicago, United States
Johns Hopkins University
Baltimore, United States
University of North Carolina
Chapel Hill, United States
Sarah Cannon Research Institute
Nashville, United States
Texas Oncology, P.A.
Dallas, United States
UT Southwestern Medical Center
Dallas, United States
The University of Texas Health Science Center at San Antonio
San Antonio, United States
Trial contact
Meredith Carter, MS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.